Nalbuphine+Naloxone, solution for injection

1. An entirely new combination. An original analgesic, which is not a scheduled drug.

2. The combination is in complete compliance with a global trend of multimodal analgesia. 

3.  The option for adequate pain control (equivalent to morphine) achieved with low doses and with minimal complications and adverse effects.

The conditions for licensing-out selling of the product.

1. Documents to be transferred:  

-     Pharmaceutical development in a CTD layout;

-    Module 3 in a CTD layout;

-    Scientific publications, literature reviews;

-    The recommended justified market price, market situation and the tentative sales targets; 

3. The generated samples for transfer and for the conduction of pre & clinical trials;

4.   The option for a technology transfer with on-site visits of specialists to the manufacturing site;